The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
fenebrutinib
Recommended Posts
- Living with MS puts me in the center of everything — literally and figuratively
- Ironically, cutting out coffee gave me a boost of energy
- MS Awareness Month events highlight advocacy, education, fundraising
- I’m going to be more open about my invisible scars from MS
- Having parents who smoked increases risk of pediatric MS: Study